Primary lymphoma of bone (PLB) is one of the rarest primary bone malignancies [1, 2] . Prognosis depends on the response to systemic chemotherapy, and, according to the response to primary treatment, subsequent treatment could be different; therefore, proper evaluation for treatment effectiveness is essential. However, evaluation of treatment effectiveness is more difficult than for other lymphomas owing to the characteristics of bone lesions [3, 4] . Evaluation for the viability of a residual tumor after chemotherapy is very important, but difficult, since viable tumors cannot easily be differentiated from bone fibrosis and remodeling lesions. Therefore, it is not easy to accurately determine complete response (CR).
A survey of 1422 non-Hodgkin's lymphoma (NHL) patients who were diagnosed at the Korea Institute of Radiological & Medical Sciences between 1989 and 2004 identified 28 patients with PLB (2%). In 18 of these cases, fluorodeoxyglucose positron emission tomography (FDG-PET) was used for evaluation of diagnosis and response, and for recurrence cases. All 18 cases were reviewed and confirmed with bone biopsy by an experienced hematopathologist. The clinical data and imaging findings of these 18 patients were monitored during treatment and follow-up period for changes in the imaging findings. All study findings were retrospectively interpreted jointly and in consensus by one radiologist and two nuclear physicians. All computed tomography (CT) or magnetic resonance imaging (MRI) scans of the involved lesions were timed to coincide with the PET images. We analyzed the clinical relevance of the separate imaging findings. The effects in staging, response and recurrence evaluation were determined according to the final clinical decisions.
The study population is summarized in Table 1 . The number of patients in whom PET findings would contribute to treatment decisions in addition to clinical findings was 15 out of 18 patients. PET contributed in the staging of 12 PBLs with polyostotic lesions. Five patients in whom there were difficulties in evaluating the response turned out to have CR during the follow-up period. The lesion finding resolved on a subsequent PET scan, with rapid decline of FDG uptake, indicating successful chemotherapy, although MRI findings were little changed. Four patients who had newly developed lesion on PET during the follow-up period showing CR turned out to have recurred, with rapid increase of FDG uptake. Those cases who were detected to have recurred resumed salvage high-dose chemotherapy with autologous hematopoietic stem-cell transplantation.
This study showed the usefulness of PET scan in PBL. Compared with CT and MRI findings before and after treatment as well as at relapse, PET scanning was found to be superior for the evaluation of response. Consequently, both over-and under-treatment can be avoided. In cases of CR, PET scanning after treatment showed no hypermetabolic lesion, with a rapid We thank Dr Cohen for his interest in our study and his useful comments. The first issue raised is the probability that the decrease in endometrial thickness and uterine
